Gray haired woman in blue shirt smiles into the camera.

Blood Clotting Therapies At
THE HEART OF HUMAN RESILIENCE.

Hemab is pioneering the first targeted preventative treatments and functional cures for underserved bleeding and thrombotic disorders—reimagining the standard of care for patients everywhere.

Our Approach

No Patient With A
Clotting Disorder

SHOULD BE
LEFT BEHIND.
While patients with common bleeding and thrombotic disorders have had access to preventative treatments for more than a half-century, no such measures exist for less-common disorders.
Young girl with glasses in a yellow sweater smiles into the camera.
For these tens of thousands of men, women, and children, life is paralyzingly unpredictable. A bleeding or thrombotic event can strike any moment, from a simple menstrual period to a routine dental procedure, and cause symptoms so severe that by the time they reach a hospital, it may be too late.
It’s time to ensure that every clotting disorder patient has the security and peace of mind they deserve.

The First-Ever Preventative Treatments For

RARE CLOTTING DISORDERS.
Hemab is leapfrogging technological advancements to deliver the first ever prophylactic treatments and functional cures for the full spectrum of genetically driven bleeding and thrombotic disorders to prevent life-threatening complications and offer patients a new lifeline. 
Essentially, the body’s bleeding and thrombosis pathway is fine-tuned, and there are numerous points within it that can fail, causing disease. Our novel therapies are designed to accumulate, modulate/balance, and at times recruit endogenous clotting factors already present in the blood to the site of injury to enable patients to form hemostatic plugs (or, clots) at the right times and in the right places.
Man with glasses in a gray sweater smiles into the camera.
Our therapeutic candidates* bind the body’s native clotting factor(s) with high specificity and affinity. This binding can stabilize the native clotting factor(s), preventing breakdown and allowing accumulation to therapeutic levels. Furthermore, the binding can be neutral (preserving the activity of the native clotting factor) or inhibitory (inactivating the clotting factor), giving us the versatility to address challenges across the clotting pathway. Our state-of-the-art technology also allows us, when necessary, to recruit native clotting factors directly to the site of injury.  
Man in green shirt hugs woman in gray sweater, both smiling into camera.

*Currently using monovalent and bispecific antibodies, with intention of expanding to other modalities

Our Pipeline

Preventing The Full Spectrum Of

BLEEDING & THROMBOTIC EVENTS.

Leveraging validated advanced technologies and key insights into the biology of clotting, Hemab’s approach is prime for widespread expansion into a range of underserved bleeding and thrombotic disorders, including Glanzmann Thrombasthenia, Factor VII Deficiency, Hemophilia B with inhibitors, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and others.

Man in a tan shirt smiles into the camera.

We are committed to finding and serving patients that have been left behind despite recent innovative therapies. Our strategic guidance, Hemab 1-2-5TM is targeting development of five clinical assets by 2025 to transform treatment for these rare disorders and enable patients everywhere to live healthy, active lives.

Hemab 1-2-5TM: 5 Clinical Assets by 2025
Program
Discovery
Preclinical
PI
PII
Program
Discovery
Preclinical
Phase I
Phase II
HMB-001 (Bleeding)
Lead candidate HMB-001 is a bispecific antibody that binds, stabilizes, and recruits endogenous factor VIIa (FVIIa) to the site of vascular injury to overcome the body’s inability to form healthy clots—building on the longstanding efficacy of recombinant FVIIa with the benefit of prophylaxis. Indicated for Glanzmann Thrombasthenia, Factor VII Deficiency, Hemophilia B with inhibitors, Bernard Soulier Syndrome
HMB-VWF (Bleeding)
HMB-VWF is designed as a prophylactic treatment for Von Willebrand Disease Type 1 and 2
HMB-TAF (Bleeding)
HMB-TAF is designed as a prophylactic treatment for Hereditary Hemorrhagic Telangiectasia and disorders of hyperfibrinolysis
HMB-AT3 (Thrombosis)
HMB-AT3 is designed as a prophylactic treatment for antithrombin (AT) deficiency
HMB-TBA
Our Team

Building The Ultimate
CLOTTING COMPANY.

Bringing together international experts in clotting biology, patient care, and drug development, the Hemab team is committed to changing the lives of patients with rare clotting disorders all around the world.

Young girl in a cheek-to-cheek hug with her mother, both smiling into the camera.
Benny Sorensen, MD, PhD
CEO
Mads Behrndt​, MSc
CFO
Johan Faber, PhD, MSc
Co-Founder, CTO
Wendy Hill, MBA
Senior Vice President of Development and Program Management
John Maraganore​, PhD
Board Chair
Linda Bain​
Director
Laura Tadvalkar​, PhD, MSc
Director
Jørgen Søberg Petersen​, MD, PhD, DSc, MBA
Director
Mårten Steen, MD, PhD
Director
Thomas Stenfeldt 
Batchelor, LL.M.
Co-Founder, Director
Camilla Petrycer Hansen, PhD, Cand. Pharm
Observer
Kristina Ekberg, LL.M.
Observer
Shan Wang, PhD
Observer
Dr. Catherine Rea, MD, PhD
Senior Director, Clinical Research
Henrik Østergaard, PhD, MSc
Scientific Director
Prafull Gandhi, PhD, MS
Scientific Director
Luke Ascolillo, MS, MPH
Director of Clinical Operations
Klaus Krainer Jønsson, MSc
Finance Director
Amalie Carnbring Bonde, PhD
Research Scientist
Helle Elisabeth Gluver Nørgaard
Senior Laboratory Technician
Louise Kempf-Amkær
Senior Laboratory Technician

Benny Sorensen, MD, PhD CEO

Benny Sorensen, MD, PhD, joined as CEO of Hemab Therapeutics from Codiak Biosciences where he served as Senior Vice President, Head of Clinical Development and Strategic Projects. During his tenure, he was involved with building the company and leading non-clinical, clinical, and regulatory affairs and advancing the first-ever engineered exosome therapeutics from idea into clinical proof of concept. Dr. Sorensen remains member of the Scientific Advisory Board at Codiak. Before Codiak, he was Senior Director of Clinical Research at Alnylam Pharmaceuticals, where he led development of fitusiran and other hematology products. Previously, he was a Global Medical Director at Baxter Healthcare Corporation advancing pivotal development of Adynovate® and Vonvendi®. He has more than 15 years of experience in clinical and translational research and management. Prior to industry, he was the Director of the Haemostasis Research Unit and Honorary Lecturer at Guy’s and St. Thomas’ Hospital & King’s College London School of Medicine, where he led basic translational research and advancement of several clinical trials across Phases I, II, and III. Dr. Sorensen earned his MD and PhD in Medicine degrees from Aarhus University, Denmark, and has published extensively in hematology translational and clinical research.

Mads Behrndt​, MSc CFO

Mads Behrndt, MSc, is CFO of Hemab. He brings more than 14 years of experience in the international capital markets as well as within strategy and business development. He joined Hemab from PwC, where he was a Partner at PwC’s Corporate Finance practice. At PwC, he led and executed private and public company financings and M&A transactions. He earned an MSc in Finance & Strategic Management from the Copenhagen Business School, Denmark.

Johan Faber, PhD, MSc Co-Founder, CTO

Johan H. Faber, PhD, MSc, is Co-Founder and the CTO of Hemab. He has more than 14 years of experience working in Novo Nordisk discovery and development of biopharmaceuticals, including leadership position and contributions to development of Novoeight®, Esperoct® and Mim8®. He holds an MSc in Pharmaceutical Sciences from Copenhagen University, Denmark, a PhD in Natural Science from Maximilian University of Würzburg, Germany, and a postdoctoral position from Imperial College London, UK.

Wendy Hill, MBA SVP OF DEVELOPMENT & PROGRAM MANAGEMENT

Wendy Hill, MBA, serves as Senior Vice President, Development & Program Management. Previously serving as Vice President of Clinical Operations at Codiak BioSciences and Senior Director of Immuno-Oncology at Genocea, she has built and executed both early- and late-stage cross-functional clinical development programs across diverse product sectors including complex supply chain platforms for per patient therapeutics. She holds a BSc in Biotechnology Engineering and an MBA from Dublin City University, Ireland.

John Maraganore​, PhD Board Chair

John Maraganore, PhD, serves as the Chair of Hemab’s Board of Directors. In his nearly 20-year tenure as the founding CEO of Alnylam, he steered the company’s efforts to pioneer RNA interference (RNAi) therapeutics, raising over $7 billion to fund its programs and establishing partnerships with more than 25 of the leading pharmaceutical and biotechnology companies. As inventor of bivalirudin, a direct-acting thrombin inhibitor later commercialized as ANGIOMAX™, and formative contributor to Fitusiran, an RNAi therapeutic targeting antithrombin for the treatment of hemophilia A or B, he has deep knowledge of thrombosis and hemostasis research and development. He has a PhD in Biochemistry and Molecular Biology from the University of Chicago, United States.

Linda Bain​ Director

Linda Bain is CFO of Codiak BioSciences. Prior to joining Codiak, she held senior roles at Adverum Biotechnologies (previously Avalanche Biotechnologies), bluebird bio, Genzyme Corporation, Fidelity Investments, and AstraZeneca. Her dedication to health equity will be key to advancing Hemab’s mission to aid underserved patients around the world. She earned a BS and an Honors degree in Accounting and Business Administration from the University of the Free State, South Africa.

Laura Tadvalkar​, PhD, MSc Director

Laura Tadvalkar, PhD, MSc, is a Principal on the Venture Team at RA Capital Management. Her primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging early-stage companies. Prior to RA, she was a Principal at MP Healthcare Venture Management. Prior to MP, she was a Consultant at Clarion Healthcare. She has a PhD in Chemical Biology from Harvard University, United States.

Jørgen Søberg Petersen​, MD, PhD, DSc, MBA Director

Jørgen Søberg Petersen, MD, PhD, DMSc, MBA, is Hemab’s immediate Past Board Chair. Dr. Pedersen trained in medicine in Denmark and in the United States. During his 20 years in the pharmaceutical industry, he served in executive R&D roles at Lundbeck, Zealand Pharma, Merck, and Novo Nordisk. He co-founded Zealand Pharma and built the company to exit. He has extensive experience in rare disease development and financing of rare disease companies and is currently a Partner at Novo Holdings. He earned an MD, PhD in Pharmacology, and DMSc from the University of Copenhagen, Denmark, and an MBA from the Technical University of Denmark.

Mårten Steen, MD, PhD Director

Mårten Steen, MD, PhD, is a partner of HealthCap. Previously, he worked as a Director of business development at Merck Serono, focusing on both product and technology licensing. Dr. Steen has pursued research in the field of protein chemistry and coagulation disorders at Lund University and Novo Nordisk. He is the author of numerous scientific papers published in peer-reviewed journals. He earned an MD and PhD in Clinical Chemistry from Lund University, Sweden.

Thomas Stenfeldt 
Batchelor, LL.M.
Co-Founder, Director